Public health & disease

Pharmacy

England to make the morning-after pill free over the counter in pharmacies

By / / Good news links

Currently, women can get the emergency contraception pill for free from sexual health clinics run by the National Health Service (NHS). However, the pill can cost up to £30 ($62) at pharmacies in the UK. Starting this year, the pill will be available for free at pharmacies, aiming to “reduce inequalities”, according to a Department of Health and Social Care (DHSC) statement. The move will also help free up general practitioners by reducing the need for women to make appointments to access the pill, the DHSC said.

​Korean scientists develop technique that detects nearly 100% of bacterial infections in under 3 hours​

By / / Good news links

Scientists at the Ulsan National Institute of Science & Technology (UNIST) in South Korea have made a major breakthrough in the accuracy and speed at which often deadly pathogen infections can be identified and treated. In many cases, this accelerated process can save lives. The new technique, known as fluorescence in situ hybridization (FISH), detected seven species of bacteria that commonly infect humans. It proved to be more than 99% accurate for all but one – a pathogen that infects skin tissue – which had a still-impressive 96.3% success rate.

A surgeon performing minimally invasive robotic surgery for an article about NeuroSafe prostate surgery

NeuroSafe prostate surgery nearly doubles odds of keeping erectile function after cancer treatment

By / / Good News For Humankind

NeuroSafe prostate surgery almost doubles the chances men retain erectile function after cancer treatment, according to the first large-scale clinical trial of the procedure. Results published in Lancet Oncology and presented at the 2025 European Association of Urology congress show 39% of NeuroSafe patients reported no or only mild erectile dysfunction at one year, compared with 23% after standard surgery — a finding that could reshape how men weigh treatment decisions.

Paris skyline at sunset

Paris residents vote to make 500 more streets pedestrian

By / / Good news links

Parisians voted to pedestrianize a further 500 of the city’s streets, giving fresh momentum to efforts by the French capital’s left-leaning town hall to curb car usage and improve air quality. The referendum will eliminate 10,000 more parking spots in Paris, adding to the 10,000 removed since 2020. The 500 additional streets to be pedestrianized will bring the total number of these so-called “green lungs” to nearly 700, just over one-tenth of the capital’s streets.

Indian flag

India has treated 6.8 million cancer patients for free in seven years

By / / Good news links

India’s Health Minister just reported that a national insurance program has treated an astonishing 6.8 million people for cancer, three-quarters of whom live in rural areas. The cost of the work amounted to $1.5 billion USD. Managed and paid for by the country’s flagship health insurance program called Ayushman Bharat, patients could get financial assistance to fight breast, oral, cervical, and lung cancers, as well as metastatic melanoma, chronic myeloid leukemia, and Burkitt’s lymphoma.

Flower floating on the water with lilies

New Delhi transforms degraded lands into biodiversity parks

By / / Good news links

New Delhi, India’s capital city, struggles with numerous environmental challenges, including extremely poor air quality and heat waves. In response, since 2004, the city has created seven large “biodiversity parks” on previously degraded land. The Aravalli Biodiversity Park, a 692-acre park located near an upscale neighborhood, is now a thriving forest of native plants. The Neela Hauz Biodiversity Park is home to a lake that was once a dumping ground for untreated sewage. All seven parks were restored by the Delhi Development Authority and the University of Delhi and together span 2,026 acres.

A medical professional preparing an injectable syringe for an article about lenacapavir HIV prevention

Annual jab for HIV protection passes trial hurdle

By / / Good news links

An annual injection designed by California’s Gilead Sciences to guard against HIV has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops the virus from replicating inside cells. For the trial, 40 people without HIV were injected into the muscle with lenacapavir, with no major side effects or safety concerns. And after 56 weeks, the medicine was still detectable in their bodies. If future trials go well, it could become the longest-acting form of HIV prevention available.

Two people holding hands

U.S. approves “milestone” Parkinson’s treatment for 2025 release

By / / Good news links

The treatment, which will be sold under the name Onapgo, is essentially a subcutaneous – under the skin – device that allows for continuous infusion of the dopamine agonist apomorphine hydrochloride to reduce ‘off’ episodes. These episodes are periods during the day and night when lepodova medication wears off and adverse motor-function symptoms become amplified. In trial, Onapgo significantly reduced these daily off episodes by an average of 2.47 hours, compared to the placebo treatment.

A doctor reviewing a prescription pad in a clinical setting for an article about non-opioid pain drug approval

FDA approves first non-opioid pain drug in more than 20 years

By / / Good News For Humankind

The FDA has approved Journavx (suzetrigine), the first non-opioid pain drug in over 20 years. The medication targets a specific sodium channel in the peripheral nervous system, blocking pain signals before they reach the brain — without engaging the pathways that make opioids addictive. The approval marks a major turning point in pain medicine, with potential implications for communities most affected by the opioid crisis.

A medical researcher reviewing cancer treatment data in a laboratory, for an article about breast cancer immunotherapy

Australian researchers nearly double cure rates for the most common breast cancer

By / / Good News For Humankind

Australian cancer researchers have nearly doubled cure rates for hormone receptor-positive breast cancer — the most common subtype worldwide — by combining breast cancer immunotherapy with standard chemotherapy. The results, focused on patients receiving treatment before surgery, mark a potentially major shift for a cancer type that has long resisted immunotherapy’s most dramatic gains.